Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH

Iida, Hiroshi; Inamori, Masahiko; Fujii, Takuma; Sekino, Yusuke; Endo, Hideki; Hosono, Kunihiro; Nonaka, Takashi; Koide, Tomoko; Takahashi, Hirokazu; Yoneda, Masato; Goto, Ayumu; Abe, Yasunobu; Kobayashi, Noritoshi; Kohno, Hiroyuki; Kubota, Kensuke; Saito, Satoru; Gotoh, Eiji; Maeda, Shin; Nakajima, Atsushi

doi:10.1186/1471-230x-12-25

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, for the resolution of heartburn symptoms, the rapid suppression of gastric acid secretion is one of the most important factors [ 23 ]. Because omeprazole with mosapride increases the intragastric pH immediately [ 10 ], it was naturally recognized as a useful on-demand therapy for patients with mild GERD. Rabeprazole with mosapride might accelerate the onset of action; it might be more suitable for on-demand therapy than rabeprazole alone.…”

Section: Discussionmentioning

confidence: 99%

“…We showed previously that the oral administration of H2RA with mosapride increased the intragastric pH more rapidly than H2RA alone [ 9 ]. In addition, our previous study showed that omeprazole orally administered 1 h after mosapride increased the intragastric pH more rapidly than omeprazole alone [ 10 ]. However, no crossover comparisons have been reported of the acid-suppressive effect of oral PPI with mosapride versus PPI alone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone

Iida¹,

Kaai²,

Inoh

et al. 2017

aog

Self Cite

View full text Add to dashboard Cite

BackgroundAn ideal medication for acid-related diseases would offer prompt stopping of blood flow as well as efficient symptom resolution. The aim of this study was to investigate the gastric acid suppression potency of a single oral dose of rabeprazole alone, compared with administration of rabeprazole plus mosapride.MethodsTwelve male volunteers, Helicobacter pylori (H. pylori)-negative, participated in this randomized, three-way crossover study. After a single oral administration of rabeprazole, rabeprazole with mosapride, or rabeprazole administered 1 h after mosapride, we monitored their intragastric pH constantly for 6 h. A 7-day washout period was allowed between each administration.ResultsThe median 6-h intragastric pH after the administration of rabeprazole 1 h after mosapride was 4.41±1.22 (mean±s.d.), significantly higher than after rabeprazole alone 3.45±1.33, P=0.0376). There was no significant difference between the median 6-h pH after the administration of rabeprazole plus mosapride and that after rabeprazole alone (3.81±0.98 vs. 3.45±1.33, respectively; P=0.0927).ConclusionAn oral dose of rabeprazole administered 1 h after mosapride increased the intragastric pH more rapidly than rabeprazole alone, in healthy, male, H. pylori-negative volunteers.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone

Iida¹,

Kaai²,

Inoh

et al. 2017

aog

Self Cite

View full text Add to dashboard Cite

show abstract

“…The achlorhydria regimen consisted of omeprazole 40 mg and aluminum hydroxide/magnesium hydroxide 200/400 mg administration 3 h prior to each EDP1066 dose. Both drugs increase the gastric pH ( 44 – 46 ) and were expected to improve the transition of EDP1066 through the stomach and into the duodenum. Omeprazole and aluminum hydroxide/magnesium hydroxide are not known to induce immune system modulation.…”

Section: Methodsmentioning

confidence: 99%

Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers

et al. 2022

View full text Add to dashboard Cite

IntroductionLactococcus lactis spp. cremoris has been associated with promising immunomodulatory results in preclinical trials. The aim of this study was to investigate the pharmacodynamic (PD) effects of three monoclonal microbial formulations of L. lactis spp. cremoris (EDP1066) on the immune response to keyhole limpet hemocyanin (KLH). Potential effects on the gut microbiota were also investigated.MethodsThe trial was registered on Netherlands Trial Register (trial ID NL7519, https://trialsearch.who.int). Eighty-one healthy subjects (median 28, range 18–59 years) were randomized to 28 days of enteric-coated capsules at five doses (n = 13) (1.5 * 1012 total cells daily), freeze-dried powder at one dose (n = 12) (3.0 * 1011 total cells daily) or five doses (n = 12), minitablets at one dose (n = 12) or five doses (n = 12), or placebo (n = 20) prior to KLH immunization. Antibody responses and circulating regulatory T cells (Tregs) were measured after KLH immunization, and skin responses were evaluated after a KLH rechallenge by laser speckle contrast imaging and multispectral imaging. Ex vivo lymphocyte (phytohemagglutinin) and monocyte (lipopolysaccharide (LPS)) cytokine release assays were explored in the minitablet-treated groups only. The prevalence of L. lactis spp. cremoris in the gastrointestinal tract and the impact on the fecal microbiota were assessed by qPCR and 16S rRNA sequencing, respectively.ResultsRepeated-measures analysis of covariances revealed no significant treatment effects on the antibody responses to KLH, number of Tregs, or KLH skin rechallenge outcomes. Ex vivo LPS-driven cytokine responses in whole blood were lower in the low dose minitablet group compared to placebo: tumor necrosis factor (estimated difference (ED) from placebo: −44.2%, 95% confidence interval (CI) −65.3% to −10.3%), interleukin (IL)-1β (ED −41.4%, 95% CI −63.5% to −5.8%), and IL-6 (ED −39.2%, 95% CI −56.8% to −14.5%). The fecal presence of L. lactis spp. cremoris increased during treatment by all EDP1066 formulations and normalized 5 days after the last dose. Microbiome α-diversity did not change by the treatments compared to placebo.DiscussionThe EDP1066 formulations did not affect the immune response to KLH immunization in healthy individuals. However, exposure to L. lactis spp. cremoris in minitablet formulation impacted ex vivo whole blood LPS cytokine response. The clinical impact of these effects awaits further investigations.Netherlands Trial Registertrialsearch.who.int, trial ID NL7519.

show abstract

“…Mosapride is less effective than PPI as monotherapy in the management of GERD and is usually used as an adjunct to PPI therapy. Coadministration of mosapride has favorable influence on pharmacokinetics of PPI by accelerating the absorption of PPI and increasing maximum plasma concentration and the area under the time-plasma concentration curve and combination therapy with mosapride and PPI increases intragastric pH more rapidly than using PPI alone [101, 102]. However, mosapride as add-on therapy to PPI in patients with erosive esophagitis fails to provide better symptom relief than placebo, and additional benefits of mosapride are only possibly seen in patients with severe symptoms [103].…”

Section: Therapy Focused On Gastroesophageal Motilitymentioning

confidence: 99%

Current Pharmacological Management of Gastroesophageal Reflux Disease

Wang

Hsu

Wang

et al. 2013

Gastroenterology Research and Practice

View full text Add to dashboard Cite

Gastroesophageal reflux disease (GERD), a common disorder with troublesome symptoms caused by reflux of gastric contents into the esophagus, has adverse impact on quality of life. A variety of medications have been used in GERD treatment, and acid suppression therapy is the mainstay of treatment for GERD. Although proton pump inhibitor is the most potent acid suppressant and provides good efficacy in esophagitis healing and symptom relief, about one-third of patients with GERD still have persistent symptoms with poor response to standard dose PPI. Antacids, alginate, histamine type-2 receptor antagonists, and prokinetic agents are usually used as add-on therapy to PPI in clinical practice. Development of novel therapeutic agents has focused on the underlying mechanisms of GERD, such as transient lower esophageal sphincter relaxation, motility disorder, mucosal protection, and esophageal hypersensitivity. Newer formulations of PPI with faster and longer duration of action and potassium-competitive acid blocker, a newer acid suppressant, have also been investigated in clinical trials. In this review, we summarize the current and developing therapeutic agents for GERD treatment.

show abstract

Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH

Cited by 7 publications

References 12 publications

Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone

Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone

Impact of oral administration of single strain Lactococcus lactis spp. cremoris on immune responses to keyhole limpet hemocyanin immunization and gut microbiota: A randomized placebo-controlled trial in healthy volunteers

Current Pharmacological Management of Gastroesophageal Reflux Disease

Contact Info

Product

Resources

About